Home › Data from Mercks Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study of Liver Diseases Annual Meeting
 

Keywords :   


Data from Mercks Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study of Liver Diseases Annual Meeting

2013-10-01 16:00:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of data from studies evaluating the companys investigational oral chronic hepatitis C virus (HCV) treatments MK-5172 and MK-8742 at the 64th American Association for the Study of Liver Diseases Annual Meeting (AASLD). The meeting is scheduled to take place in Washington, D.C., Nov. 1-5, 2013. Language: English Contact: MerckMedia:Sarra Herzog, 908-423-6154orInvestor:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: of data american study

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.05Indian spices face heat over global safety concerns
15.05'Corrupt ship inspectors demand our food and cargo'
15.05Taylor Swift Eras Tour to boost UK spending by 1bn, says report
15.05Three ways to win the rental property race
15.05Renters in scrum for homes as listing time slashed
14.05Nu Skin Releases 2023 Social Impact and Sustainability Report
14.05P&G Unveils Plans to Feature Brands During the Olympic and Paralympic Games Paris 2024
14.05The LOccitane Group Appoints Evelyne LY-Wainer Managing Director Global Travel Retail
More »